Journal of Psychopharmacology
May 1, 2024
Thomas Knuijver, Rob Ter Heine, Arnt Schellekens et al.
15 citations
Ibogaine is a hallucinogenic drug that may be used to treat opioid use disorder (OUD). The relationships between pharmacokinetics (PKs) of ibogaine and its metabolites and their clinical effects on side effects and opioid withdrawal severity are unknown. We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. The study was performed in 14...
The Journal of Clinical Psychiatry
April 24, 2024
Gregory H Jones, Courtney M Vecera, Ana C Ruiz et al.
13 citations
Objective: Although individuals with a family history of alcohol use disorder (AUD) have a superior antidepressant response to ketamine, outcomes in patients with current AUD remain unclear. This study sought to investigate whether intranasal (IN) racemic (R,S)-ketamine had antisuicidal and antidepressant effects in unipolar and bipolar depression and whether comorbid AUD conferred superior...
Neurology
April 9, 2024
Tina Singh, Dipa Patel, Kasey Bishop et al.
1 citation
To uncover the underlying mechanisms between the usage of psilocybin and its impact on the rehabilitation from substance use disorders (SUD).
Addiction
April 1, 2024
Sammie Back, Emese Kroon, Karis Colyer-Patel et al.
AbstractBackgroundPrevalence of nitrous oxide (N2O) use appears to be increasing in numerous countries worldwide, and excessive use has been associated with physical and mental problems. Because there currently is no consensus whether N2O has addictive potential, we aimed to evaluate the evidence for the presence and prevalence of DSM‐5 substance use disorder (SUD) symptoms in N2O...
Journal of Clinical and Translational Science
April 1, 2024
Broc A. Pagni, Petros Petridis, Samantha K. Podrebarac et al.
1 citation
OBJECTIVES/GOALS: This pilot study investigated psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder (AUD). METHODS/STUDY POPULATION: Participants were recruited from a phase II, randomized, double-blind, placebo-controlled clinical trial investigating psilocybin-assisted therapy (PAT) for the treatment of AUD (NCT02061293). Eleven...
JAMA Psychiatry
April 1, 2024
Nina A Cooperman, Shou-En Lu, Adam W. Hanley et al.
39 citations
Methadone treatment (MT) fails to address the emotion dysregulation, pain, and reward processing deficits that often drive opioid use disorder (OUD). New interventions are needed to address these factors. To evaluate the efficacy of MT as usual (usual care) vs telehealth Mindfulness-Oriented Recovery Enhancement (MORE) plus usual care among people with an OUD and pain. This study was a...
Addiction Biology
April 1, 2024
Stephan Tap
12 citations
Abstract Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment options show modest efficacy and relapse rates are high. Furthermore, there are increases in the treatment gap and few new medications have been approved in the past 20 years. Recently, psychedelic‐assisted therapy with psilocybin and lysergic acid...
Brain Sciences
March 27, 2024
James Chmiel, Agnieszka Malinowska, Filip Rybakowski et al.
4 citations
Methamphetamine is a highly stimulating psychoactive drug that causes life-threatening addictions and affects millions of people around the world. Its effects on the brain are complex and include disturbances in the neurotransmitter systems and neurotoxicity. There are several known treatment methods, but their effectiveness is moderate. It must be emphasised that no drugs have been approved...
Journal of Studies on Alcohol and Drugs
March 22, 2024
David Nutt, Celia J. A. Morgan, Sukhpreet Klaire
This Perspectives piece gives a brief overview on the last 70 years of psychedelic research in relation to the treatment of mental illness with a particular focus on addictions. We briefly precis the work in the 19650s/60s that started following the discovery of LSD. Then we overview research developments over the past twenty years driven by emerging neuroscience on these agents, the rise of...
Brain Sciences
March 20, 2024
Muhammet Celik, Mark S. Gold, Brian S Fuehrlein
22 citations
Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the...